Nervgen Pharma Corp (NGEN) Stock Price, Quote & News

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology

Sector: Healthcare

Phone: 778-731-1711

Website: www.nervgen.com

Address:

112-970 Burrard Street, Unit 1290, Vancouver, Canada

TH3_PR0F1T Mar. 15 at 7:37 PM

$NGEN

1 · Reply

KGEEEZY Mar. 15 at 2:06 PM

$NGEN If we get news that NGEN has received Accelerated Access this stock is MOOOOONING!!!

2 · Reply

DavesStockPicks Mar. 14 at 12:33 AM

$NGEN We're still in an upward trend. It'll soon test the moving average here soon and we'll have confirmation if that trend will continue or not.

1 · Reply

TH3_PR0F1T Mar. 14 at 12:25 AM

$NGEN Can anyone speak to NGEN leadership? Anything noteworthy? Reason I ask is it looks like they've been shuffling the deck a little.

0 · Reply

TH3_PR0F1T Mar. 13 at 11:27 PM

$NGEN End of Phase 2 FDA meeting very soon.

2 · Reply

Eldorado_Toole Mar. 13 at 9:09 PM

$NGEN Need to watch a video, it'll make you feel better... "222 seconds to 21 seconds" https://vimeo.com/1139656943/8028c1f465?fl=pl&fe=sh

4 · Reply

aladdinscarpet Mar. 13 at 6:57 PM

$NGEN Know what you own

6 · Reply

alexandredaigneault96 Mar. 13 at 6:05 PM

$NGEN why the hell is this stock going down everyday. Need positive FDA meeting to come ASAP.

1 · Reply

TH3_PR0F1T Mar. 13 at 5:35 PM

$NGEN We're taking an unjustified beat down today...

2 · Reply

Tarquinjones Mar. 13 at 5:24 PM

$NGEN

0 · Reply

NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exchange

Feb 18, 2026, 7:30 AM EST - 26 days ago

NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 12, 2026, 4:15 PM EST - 4 weeks ago

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

Feb 11, 2026, 7:00 AM EST - 4 weeks ago

NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium

2026-02-09T13:00:58.000Z - 5 weeks ago

NervGen Pharma Appoints Adam Rogers As CEO

2026-02-09T12:28:05.000Z - 5 weeks ago

NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291

Feb 9, 2026, 7:00 AM EST - 5 weeks ago

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

2026-02-09T12:00:00.000Z - 5 weeks ago

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

2026-01-08T13:39:25.000Z - 2 months ago

NervGen Pharma Debuts On Nasdaq

Jan 8, 2026, 6:30 AM EST - 2 months ago

NervGen Pharma Begins Trading on Nasdaq Today

Dec 17, 2025, 4:18 PM EST - 3 months ago

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Dec 12, 2025, 7:51 PM EST - 3 months ago

NervGen Pharma Announces Proposed Amendment to Warrants

Nov 24, 2025, 7:05 AM EST - 4 months ago

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Nov 24, 2025, 7:00 AM EST - 4 months ago

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Nov 19, 2025, 4:26 PM EST - 4 months ago

NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Nov 18, 2025, 4:42 PM EST - 4 months ago

NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Aug 26, 2025, 7:30 AM EDT - 7 months ago

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

Aug 21, 2025, 7:30 AM EDT - 7 months ago

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Jul 17, 2025, 7:30 AM EDT - 8 months ago

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Jul 7, 2025, 5:30 PM EDT - 8 months ago

NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update

Jul 3, 2025, 4:41 PM EDT - 9 months ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Jul 1, 2025, 7:30 AM EDT - 9 months ago

NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones

Jun 18, 2025, 7:30 AM EDT - 9 months ago

NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role

May 21, 2025, 7:30 AM EDT - 10 months ago

NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting

May 16, 2025, 4:30 PM EDT - 10 months ago

NervGen Pharma Grants Stock Options

May 15, 2025, 7:30 AM EDT - 10 months ago

NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates

May 7, 2025, 7:30 AM EDT - 11 months ago

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Apr 21, 2025, 7:30 AM EDT - 11 months ago

NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 9, 2025, 5:53 PM EDT - 1 year ago

NervGen Provides Quarterly "At-The-Market" Equity Program Update

Apr 3, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event

Fri, 14 Mar 2025 19:27:00 -0400 - 1 year ago

NervGen Pharma Grants Stock Options

Mar 5, 2025, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Virtual Life Science Investor Forum

Tue, 18 Feb 2025 16:30:00 -0500 - 1 year ago

NervGen Pharma Grants Stock Options

Feb 6, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Jan 29, 2025, 5:00 PM EST - 1 year ago

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 2, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program

Nov 14, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Nov 7, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

TH3_PR0F1T Mar. 15 at 7:37 PM

$NGEN

1 · Reply

KGEEEZY Mar. 15 at 2:06 PM

$NGEN If we get news that NGEN has received Accelerated Access this stock is MOOOOONING!!!

2 · Reply

DavesStockPicks Mar. 14 at 12:33 AM

$NGEN We're still in an upward trend. It'll soon test the moving average here soon and we'll have confirmation if that trend will continue or not.

1 · Reply

TH3_PR0F1T Mar. 14 at 12:25 AM

$NGEN Can anyone speak to NGEN leadership? Anything noteworthy? Reason I ask is it looks like they've been shuffling the deck a little.

0 · Reply

TH3_PR0F1T Mar. 13 at 11:27 PM

$NGEN End of Phase 2 FDA meeting very soon.

2 · Reply

Eldorado_Toole Mar. 13 at 9:09 PM

$NGEN Need to watch a video, it'll make you feel better... "222 seconds to 21 seconds" https://vimeo.com/1139656943/8028c1f465?fl=pl&fe=sh

4 · Reply

aladdinscarpet Mar. 13 at 6:57 PM

$NGEN Know what you own

6 · Reply

alexandredaigneault96 Mar. 13 at 6:05 PM

$NGEN why the hell is this stock going down everyday. Need positive FDA meeting to come ASAP.

1 · Reply

TH3_PR0F1T Mar. 13 at 5:35 PM

$NGEN We're taking an unjustified beat down today...

2 · Reply

Tarquinjones Mar. 13 at 5:24 PM

$NGEN

0 · Reply

DavesStockPicks Mar. 12 at 10:56 PM

$NGEN To remove the listing from the TSX Venture. Will now be on the NASDAQ exclusively.

3 · Reply

Eldorado_Toole Mar. 12 at 9:47 PM

$NGEN I'm glad to see a new post. I have not been able to post or see new posts all day up til just now. Anyone else having issues?

3 · Reply

NVG291Fan Mar. 12 at 8:56 PM

$NGEN $NGEN $NGEN We delisted on the TSX. Interesting only a few hundred shares were issued through the ATM this quarter. The trading patterns have been interesting….. A lot like the late Fall patterns last year when I also thought we were issuing shares (but weren’t). https://finance.yahoo.com/news/nervgen-pharma-announces-voluntary-delisting-201500795.html

1 · Reply

indigolight Mar. 12 at 8:51 AM

$NGEN https://youtu.be/7CI3H-HDtgU?si=vct8cEaTDA_1Y9ZW Looking further the video clearly shows the great anticipation and advocacy patient groups are showing for NVG291. It is getting known among the SCI population that a drug has worked for participating patients in a trial and it is not released yet at the level of drug agency. I wonder how much patience and enduring silence the SCI community can bear before demanding a swift acces to the first drug in history that has shown SCI recovery?

2 · Reply

Skaped Mar. 11 at 7:16 PM

$NGEN https://youtu.be/7CI3H-HDtgU?si=vct8cEaTDA_1Y9ZW This conference from Feb 15-17 was not live streamed, but is now available to watch. Adam’s initial presentation is at 2h14m. The QA with Adam and two others is at 2h36m.

1 · Reply

Shivanzu Mar. 11 at 4:59 PM

$NGEN Is there a holiday on StockTwits today? It seems unusually quiet.

0 · Reply

Zeppieddodaw Mar. 11 at 1:39 PM

$NGEN $NGEN I think any exposure is good for the drug and Company. However for myself I never plan on getting on X for various reasons. But thanks to you all who promote NGEN there.

1 · Reply

DavesStockPicks Mar. 10 at 5:32 PM

$NGEN If any of you aren't on Twitter/X and you don't gag at the thought of signing up, us NervGeners could help with giving $NGEN more exposer there. It's mostly like a handful of us and one guy that makes too many AI gifs begging Elon to invest in NervGen, lol.

3 · Reply

Tarquinjones Mar. 10 at 4:11 PM

$NGEN Hang onto your hats https://www.biospace.com/fda/senator-ron-johnson-launches-investigation-into-fda-rare-disease-rejections

2 · Reply

CCbank Mar. 10 at 1:55 PM

$NGEN seriously wat was that bs in premarket. something is brewing

2 · Reply

N123C567 Mar. 10 at 11:43 AM

$NGEN

1 · Reply

Shivanzu Mar. 10 at 8:55 AM

$NGEN why?? What happen.24%

4 · Reply

Market Cap	N/A
Revenue (ttm)	46.92M
Net Income (ttm)	-38.10M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	0.00
Profit Margin	-81.20%
Debt to Equity Ratio	N/A

Volume	775,700
Avg Vol	145,364
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	80%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A